Zeitschrift für klinische Krebsstudien

An Overview of Immune Checkpoint Inhibitors in the Treatment of Gynecological Cancer

Abstract

Youssef El-Sayed

Immune Checkpoint Inhibitors (ICIs) have emerged as a groundbreaking therapeutic modality in the field of oncology, offering new hope for patients with various types of cancer, including gynecological malignancies. These inhibitors target immune checkpoints, key regulators of the immune system, to enhance the body's antitumor response. This article provides an extensive overview of the role of ICIs in the treatment of gynecological cancers, including cervical, ovarian, and endometrial cancers. It discusses the mechanism of action, clinical efficacy, ongoing research, and future prospects of these therapies. The literature review highlights key clinical trials and studies that have shaped the current understanding of ICIs in gynecological oncology. Furthermore, the discussion section addresses the challenges, limitations, and potential strategies to overcome these obstacles. The conclusion emphasizes the significance of continued research and personalized approaches in optimizing the use of ICIs for gynecological cancer patients.